Impact of Formulation on the Pharmacokinetic Profile of Dutasteride

Claus G. Roehrborn, Igor Oyarzabal Perez, Erik P.M. Roos, Nicolae Calomfirescu, Betsy Brotherton, Fang Wang, Juan Manuel Palacios, Averyan Vasylyev, Michael J. Manyak, Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJUI. ,vol. 116, pp. 450- 459 ,(2015) , 10.1111/BJU.13033

Michael J. Fossler, David A. Collins, Meg M. Thompson, Antonio Nino, Joseph J. Bianco, Dushen Chetty, Pharmacokinetic Bioequivalence Studies of a Fixed-Dose Combination of Tamsulosin and Dutasteride in Healthy Volunteers Clinical Drug Investigation. ,vol. 34, pp. 335- 349 ,(2014) , 10.1007/S40261-014-0179-0

Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Michael Shear, Jonathan Davies, Adrian Quartel, Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation European Urology Supplements. ,vol. 4, pp. 53- 60 ,(2005) , 10.1016/J.EURSUP.2004.11.005

Claus G. Roehrborn, Paul Siami, Jack Barkin, Ronaldo Damião, Kim Major-Walker, Indrani Nandy, Betsy B. Morrill, R. Paul Gagnier, Francesco Montorsi, Corrigendum to “The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study” [Eur Urol 2010;57:123–31] European Urology. ,vol. 58, pp. 801- 801 ,(2010) , 10.1016/J.EURURO.2010.07.035

Matthias Oelke, Alexander Bachmann, Aurélien Descazeaud, Mark Emberton, Stavros Gravas, Martin C. Michel, James N'Dow, Jørgen Nordling, Jean J. de la Rosette, EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction European Urology. ,vol. 64, pp. 118- 140 ,(2013) , 10.1016/J.EURURO.2013.03.004

Roger S Kirby, Claus Roehrborn, Peter Boyle, Georg Bartsch, Alain Jardin, Margaret M Cary, Michael Sweeney, Eric B Grossman, PREDICT Study Investigators, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology. ,vol. 61, pp. 119- 126 ,(2003) , 10.1016/S0090-4295(02)02114-3

Claus G. Roehrborn, Paul Siami, Jack Barkin, Ronaldo Damião, Kim Major-Walker, Indrani Nandy, Betsy B. Morrill, R. Paul Gagnier, Francesco Montorsi, The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study European Urology. ,vol. 57, pp. 123- 131 ,(2010) , 10.1016/J.EURURO.2009.09.035

F.M.J. Debruyne, A. Jardin, D. Colloi, L. Resel, W.P.J. Witjes, M.C. Delauche-Cavallier, C. McCarthy, C. Geffriaud-Ricouard, Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia European Urology. ,vol. 34, pp. 169- 175 ,(1998) , 10.1159/000019706

Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers, The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS European Urology Supplements. ,vol. 4, pp. 15- 24 ,(2005) , 10.1016/J.EURSUP.2004.11.002

John D. McConnell, Claus G. Roehrborn, Oliver M. Bautista, Gerald L. Andriole, Christopher M. Dixon, John W. Kusek, Herbert Lepor, Kevin T. McVary, Leroy M. Nyberg, Harry S. Clarke, E. David Crawford, Ananias Diokno, John P. Foley, Harris E. Foster, Stephen C. Jacobs, Steven A. Kaplan, Karl J. Kreder, Michael M. Lieber, M. Scott Lucia, Gary J. Miller, Mani Menon, Douglas F. Milam, Joe W. Ramsdell, Noah S. Schenkman, Kevin M. Slawin, Joseph A. Smith, The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia New England Journal of Medicine. ,vol. 349, pp. 2387- 2398 ,(2003) , 10.1056/NEJMOA030656